Up to 3% of people have psoriasis, and as many as 42% of these have an associated chronic inflammatory arthritis.1 In up to 20% of such patients, the arthritis progresses to become severe, destructive and deforming.2–5 Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. ▼Leflunomide (Arava - Sanofi-Aventis), ▼etanercept (Enbrel - Wyeth) ▼inifliximab (Remicade - Schering-Plough) and ▼adalimumab (Humira - Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.